|

CD19- BCMA CAR-T cells Clinical Trials

1 actively recruiting trial

Also known as: EB-BH2024-2

Pipeline

Phase 1/2: 1

Top Sponsors

  • Essen Biotech1

Indications

  • Microscopic Polyangiitis1
  • Granulomatous Polyangiitis1
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis1
  • Systemic Sclerosis1
  • Lupus Nephritis1

Other1 trial

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.